Biopharmaceutical Characterisation of Herbal Medicinal Products FIP Recommendations The FIP Special Interest Group (SIG) Quality of Pharmaceuticals established in 1999 a working group aiming to elaborate recommendations for biopharmaceutical characterisation of Herbal Medicinal Products (HMPs). Considering the current European and American regulatory guidelines on quality for HMPs it was felt there is the need for clarification of biopharmaceutical characteristics taking into account the classification of HMPs.
The FIP Working group Herbal Medicinal Products (HMPs) which elaborated the following recommendations consists of following experts: Dr. Friedrich Lang (Dr. Willmar Schwabe Arzneimittel, Karlsruhe, Germany), chair of the group, Prof. Dr. Konstantin Keller (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany), Dr. Michael Ihrig (Zentrallaboratorium Deutscher Apotheker, Eschborn, Germany), Joy Oudtshoorn-Eckard (Johannisburg, South Africa), Prof. Dr. Helga Möller (Zentrallaboratorium Deutscher Apotheker, Eschborn, Germany), Dr. Srini Srinivasan (United States Pharmacopoeia, Rockville, USA), Dr. Yu He-ci (Hankintatukku OY, Finnland).
Comments on the draft will be highly appreciated by the authors until 31 March 2002, to the attention of: Dr. Friedrich Lang, Mailbox 410925, 76209 Karlsruhe (Germany) |
